Bleichroeder Advisors increases stake to 13.1% in Genelabs

By E. Janene Geiss

Philadelphia, Oct. 31 - Arnhold and S. Bleichroeder Advisors LLC increased its investment to 13.1% in Genelabs Technologies, Inc. as of Oct. 24, according to an SC 13G/A filing with the Securities and Exchange Commission.

The passive stake represents 5,800,474 shares.

Those holdings are up from the passive stake of 10.65%, or 4,670,103 shares, that Bleichroeder reported on July 31, 2008, according to an earlier SC 13G filings.

According to other previous SC 13G filings, the company reported holdings of 6.35%, or 2,773,520 shares, on Dec. 31, 2007. It reported ownership of 1,810,189 shares, or a 7.53% passive stake, on Dec. 31, 2006.

Redwood City, Calif.-based Genelabs is a global biopharmaceutical and diagnostics company specializing in gene-regulating drug discovery, infectious diseases including hepatitis, and immunological disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.